Bio
Kavita Iyer graduated with a Bachelor of Pharmacy from the University of Mumbai. Subsequently she earned her PhD in Medicinal Chemistry from Virginia Commonwealth University, VCU. She further pursued a post-doctoral fellowship in the Department of Physiology and Biophysics at VCU where she was trained as a structural biologist and subsequently worked as a Research Scientist. While at CAS, Kavita has worked on a wide range of topics including immuno-oncology, CRISPR therapeutics, rare diseases, and nano biosensors in Life Sciences as well as covalent inhibitors and PROTACs in Medicinal Chemistry.
Biotecnologia
O xenotransplante poderia resolver a escassez de órgãos para transplante?
Com o advento da tecnologia de edição genética, os pesquisadores estão cada vez mais aptos a lidar com questões de imunocompatibilidade, aproximando-se de tornar órgãos e tecidos disponíveis para transplante de doadores animais para receptores humanos.
Drug Discovery
PPI inhibitors show promise in cancer trials
Small molecule PPI inhibitors are on the brink of improving cancer treatments
Emerging Science
Co-occurring concepts reveal new research directions in immuno-oncology
Concept co-occurrence analysis shows the newest ideas in scientific discovery and drives innovation in immuno-oncology.
Drug Discovery
PROTACs revolutionize small molecule drugs
PROTACs are driving small molecule drug development to treat cancer, neurodegenerative diseases and more
Biotecnologia
Webinar: Big data insights in the quest to cure cancer
Experts discuss emerging trends in immuno-oncology, data challenges, and opportunities ahead for cancer researchers.
Drug Discovery
Emerging trends in immunotherapy and cancer
Immuno-oncology has the potential to treat cancer without sacrificing the patient's wellbeing.